Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | MGLL | Q99685 | 2/20 | 0.67 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6235216 | 0.87 | MEN1 (1.00) | KMT2AMEN1MGLLHSD11B1ALDH1A1 | |
| SCHEMBL12302035 | 0.85 | KMT2A (0.74) | KMT2AMEN1GAAMGLLHSD11B1 | |
| SCHEMBL1720669 | 0.84 | MEN1 (0.88) | KMT2AMEN1MGLLHSD11B1ALDH1A1 | |
| SCHEMBL1673861 | 0.84 | MAPT (0.73) | KMT2AMEN1MAPTGAAMGLL | |
| SCHEMBL29067078 | 0.83 | MAPT (0.71) | KMT2AMEN1MAPTGAAMGLL | |
| SCHEMBL1534281 | 0.83 | MAPT (1.00) | KMT2AMEN1MAPTGAAMGLL | |
| SCHEMBL3305635 | 0.83 | HSD11B1 (0.77) | KMT2AMEN1MAPTGAAMGLL | |
| SCHEMBL10274557 | 0.83 | ACHE (0.72) | KMT2AMEN1MGLLHSD11B1ALDH1A1 | |
| SCHEMBL12074789 | 0.83 | KMT2A (0.71) | KMT2AMEN1MGLLHSD11B1ALDH1A1 | |
| SCHEMBL14817987 | 0.83 | ALDH1A1 (0.72) | KMT2AMEN1MGLLHSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058877-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC | 2004-03-25 | — | — | US | claimed |
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | HAY BRUCE A (US) | 2002-09-12 | — | — | US | claimed |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC. | 2002-02-07 | — | — | US | claimed |
| EP-1086947-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | Pfizer Products Inc. (US) | 2001-03-28 | — | — | EP | claimed |
| EP-1757582-B1 | ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-30 | — | — | EP | disclosed |
| US-8759387-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-06-24 | — | — | US | disclosed |
| US-8759387-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-06-24 | — | — | US | disclosed |
| US-8703721-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-03-20 | — | — | US | disclosed |
| US-8492111-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-23 | — | — | US | disclosed |
| US-8492111-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100249049-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MIYAZAKI HIROSHI | 2010-09-30 | — | — | US | disclosed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20040058877-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC | 2004-03-25 | — | — | US | disclosed |
| US-6696418-B1 | ANIMAL GROWTH REGULATORS SUCH AS 6-AMINO-2-(2-((1-BENZENE SULFONYL-PIPERIDINE-4-CARBONYL)-AMINO)-3-(1H-INDOL-3-YL)-PROPIONYLAMINO) -HEXANOIC ACID TERT-BUTYL ESTER, ADMINISTERED TO MODULATE CELL DIFFERENTIATION | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | HAY BRUCE A (US) | 2002-09-12 | — | — | US | disclosed |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| EP-1086947-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | Pfizer Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | KMT2A 2405/4885MEN1 564/4885MAPT 4092/4885 |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | KMT2A 2464/4885MEN1 639/4885MAPT 4154/4885 |
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | NAT1, INMT, ARSA | KMT2A 1036/4885MEN1 3338/4885MAPT 2320/4885 |
| US-20040058877-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | KMT2A 2464/4885MEN1 639/4885MAPT 4154/4885 |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | CASR, CNR1, CNR2 | KMT2A 1688/4885MEN1 3040/4885MAPT 4514/4885 |
| US-20100249049-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | CASR, CNR1, CNR2 | KMT2A 1688/4885MEN1 3040/4885MAPT 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.